[ad_1]
This morning the news of the approval of the Pfizer vaccine in the United Kingdom, the first western country to provide it by relying on the markets and beyond.
The British regulator authorized the treatment born of the collaboration between the United States. Pfizer and german BioNTechwhile US and EU approvals are still pending.
However, highlight many economists in the last hours, first of all Ana nicholls by The Economist Intelligence Unit: This is a decision that could “Setting the pace for the rest of the world” .
The emergency approval of the coronavirus vaccine will thus lead other countries to follow suit, giving the green light very soon to the preparation that has been estimated 95% effective in advanced clinical phase tests.
Vaccine approval in the UK? “He will give it to others.” Opinion
The UK is the first country in the world to formally approve the Pfizer vaccine, so much so that the CEO, Albert bourla, defined the decision as moved “A historical moment”.
Regulators in the US and Europe are now likely to push soon to complete your evaluations on the safety and efficacy of available vaccine data, according to many economists and market watchers:
“UK approval will be just one of many, but together with that of the US Food and Drug Administration and the European Medicines Agency, it is likely to set the pace for the rest of the world and the other vaccines. that are awaiting approval “,
Ana Nicholls, editor-in-chief of The Economist Intelligence Unit, commented on Wednesday.
For the UK, today’s approval means categories so-called sensitive they can start getting vaccinated early – this includes healthcare workers, nursing home staff and residents, and other groups considered vulnerable.
Pfizer and BioNTech submitted a request to the EMA on Tuesday Marketing authorization of the vaccine. If granted, it could be used starting this month.
Ema herself announced that she would conclude her review of the “rival” vaccine of the Pfizer preparation, namely the one developed by Moderna, before January 12.
